| Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
258 |
| SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review |
99 |
| Global trends in diabetes complications: a review of current evidence |
98 |
| Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation |
75 |
| Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease |
69 |
| Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25year period 1989-2013: a multicentre prospective registration study |
62 |
| Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study |
52 |
| Epidemiology of diabetes and diabetic complications in China |
47 |
| The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure |
47 |
| Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis |
47 |
| Neurodegeneration in diabetic retinopathy: does it really matter? |
43 |
| Aberrant intestinal microbiota in individuals with prediabetes |
43 |
| Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease |
34 |
| Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOMEA (R) trial |
34 |
| Development of SGLT1 and SGLT2 inhibitors |
31 |
| Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program |
31 |
| Unique metabolic activation of adipose tissue macrophages in obesity promotes inflammatory responses |
31 |
| Physiology of renal glucose handling via SGLT SGLT2 and GLUT2 |
29 |
| New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism |
28 |
| DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality |
28 |
| Maternal glucose levels during pregnancy and childhood adiposity in the Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study |
27 |
| Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and meta-analysis |
26 |
| Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial |
26 |
| Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study |
26 |
| No direct effect of SGLT2 activity on glucagon secretion |
26 |
| Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond |
26 |
| Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) |
25 |
| Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events |
25 |
| Use of human islets to understand islet biology and diabetes: progress, challenges and suggestions |
25 |
| GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study |
24 |
| HbA(1c), diabetes and cognitive decline: the English Longitudinal Study of Ageing |
24 |
| Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course |
24 |
| Intrauterine programming of obesity and type 2 diabetes |
24 |
| Biomarkers of diabetic kidney disease |
24 |
| Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997-2011 |
24 |
| Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose |
24 |
| Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study |
24 |
| Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes |
23 |
| Marked improvement in HbA(1c) following commencement of flash glucose monitoring in people with type 1 diabetes |
23 |
| Afternoon exercise is more efficacious than morning exercise at improving blood glucose levels in individuals with type 2 diabetes: a randomised crossover trial |
23 |
| Cellular senescence: at the nexus between ageing and diabetes |
21 |
| Diabetes in pregnancy: a new decade of challenges ahead |
21 |
| Plasma branched chain/aromatic amino acids, enriched Mediterranean diet and risk of type 2 diabetes: case-cohort study within the PREDIMED Trial |
21 |
| lncRNA H19 prevents endothelial-mesenchymal transition in diabetic retinopathy |
21 |
| Lipid environment induces ER stress, TXNIP expression and inflammation in immune cells of individuals with type 2 diabetes |
20 |
| Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals |
20 |
| Diabetes and pregnancy: national trends over a 15 year period |
20 |
| Exercise training decreases pancreatic fat content and improves beta cell function regardless of baseline glucose tolerance: a randomised controlled trial |
19 |
| Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits |
19 |
| Beta cells in type 1 diabetes: mass and function; sleeping or dead? |
19 |
